The congenital hyperinsulinism pipeline includes 4+ active companies and 4+ therapies across clinical and nonclinical stages. Zealand Pharma advanced dasiglucagon in January 2026, while RZ358 is in Phase III evaluation.
Recent research explores outcomes when patients stop GLP-1 medications and finds pharmacist-led interventions can help older adults avoid dangerous low blood sugar episodes.
Novo Nordisk struggles against Eli Lilly in the weight loss market as CagriSema underperforms Zepbound, though new candidate UBT251 shows promise with 19.7% weight loss in 24 weeks. The company expects sales to decline in 2026 despite oral Wegovy's success.
Novo Nordisk's experimental triple-action obesity drug UBT251 achieved up to 19.7% weight loss in a Phase 2 trial in China, as the company works to regain ground against rival Eli Lilly in the obesity drug market.
New research shows semaglutide cuts cardiovascular event risk by 4% per 5kg weight loss, with two-thirds of heart benefits unexplained by weight reduction alone. Study of 17,604 participants suggests multiple protective mechanisms beyond weight loss.
